Cancer chemoprevention can be defined as prevention of cancer by the administration of one or more chemical entities, either as individual drugs or as naturally occurring constituents of the diet. Based largely on the time period that chemopreventive agents exhibit activity in animal models of carcinogenesis, they can be classified as inhibitors of carcinogen formation, blocking agents, and suppressing agents. The majority of compounds that inhibit the formation of carcinogens prevent the formation of nitrosamines from secondary amines and nitrite in an acidic environment. Blocking agents are inhibitors of tumor initiation, while suppressing agents are inhibitors of tumor promotion/progression. Many well-characterized chemopreventive agents act at one or more steps in both tumor initiation and promotion/progression. The objective of this paper is to provide a general discussion of the mechanisms through which chemopreventive agents inhibit carcinogenesis. Examples of agents that act through these mechanisms are given; however, a complete listing of effective chemopreventive agents is not possible within the context of this paper. At the conclusion is a brief discussion of future prospects in cancer chemoprevention and obstacles to overcome. Environ Health Perspect 1 05(Suppl 4): 945-954 (1997) 
Introduction
Cancer chemoprevention can be defined as the prevention, inhibition, or reversal of carcinogenesis by administration of one or more chemical entities, either as individual drugs or as naturally occurring constituents of the diet. Knowledge of chemoprevention science and its application in clinical studies has been growing rapidly over the past decade, as has been documented in reviews of the field prepared by us and by others (1) (2) (3) (4) (5) (6) (7) (8) . This paper serves as an update and brief commentary on the status and various aspects of chemoprevention.
Epidemiological studies indicate that approximately 80% of human cancer is caused by exposure to chemical carcinogens in tobacco smoke, in the diet, and in the workplace (9, 10) . Given these observations, at least three approaches to the prevention of cancer can be envisioned. First, reduce human exposure to environmental carcinogens through careful monitoring of the workplace and through educational approaches to encourage changes in lifestyle. Second, identify individuals at high risk for cancer development through predisposing genetic or biochemical factors, followed by appropriate clinical follow-up. Third, provide chemoprevention by dietary or synthetic means. For several reasons, chemoprevention has received growing consideration as a means of cancer control. In certain organ sites such as the lung, pancreas, stomach, ovary, and esophagus, the development of cancer leads to exceptionally low 5-year survival rates. Clearly, the considerable TGF-3, transforming growth factor 0; TPA, 1 2-0-tetradecanoylphorbol-1 3-acetate; UDC, urine diphosphate.
advances that have occurred in earlier detection and treatment of cancer have done little to improve the prognosis for patients diagnosed with cancer at certain organ sites. Primary cancer prevention requires removal of exposure to etiologic agents. Although this is an important approach to cancer prevention, it is not always effective, as evidenced by the marginal success of tobacco cessation programs. Moreover, numerous populations at high risk for certain types of cancer may already have received considerable exposure to etiologic agents, and many human cancers cannot be ascribed to specific agents. Thus, preventive strategies that do not require prior knowledge of specific etiological factors have great appeal. Additionally, the success obtained in chemoprevention of cancer in animal models provides a strong mandate for this approach to cancer prevention in humans.
Target Populations
The projected target populations for cancer chemoprevention consist of high-risk groups, such as the following: individuals with high exposure to carcinogens (e.g., tobacco smokers and populations that consume foodstuffs contaminated with fungal toxins and nitrosamines); those who are known to be genetically predisposed to the development of cancer (e.g., patients with familial colonic polyposis); individuals with premalignant lesions (e.g., oral leukoplakia, Barrett (36, 37) .
Inducers of Cytoehrome P450 Enzymes. Another mechanism of action of blocking agents is through induction of cytochrome P450. Inducers of cytochrome P450 act either by increasing the metabolic activation of carcinogens in nontarget tissues or by enhancing oxidative detoxification at any tissue site. Indole-3-carbinol (I3C) is a potent inducer of P450 enzymes and has chemopreventive activity in several animal models (38) (39) (40) (41) (42) (43) (44) . Compounds that induce P450 enzymes, however, may promote cancer at other organ sites through enhanced carcinogen activation at these sites; this may, at least in part, account for the known cocarcinogenic or promotional activity of 13C (45) (46) (47) .
Inducers Phase II Enzymes. Inducers of phase II detoxifying enzymes are preferred to cytochrome P450 inducers as chemopreventive agents because they are less likely to produce cancers themselves. Sulforaphane, an isothiocyanate found in broccoli (48) , is a potent inducer of GST and inhibits chemically induced mammary cancer in rats (49) . Another potent inducer of GST is the dithiolethione, oltipraz, which inhibits carcinogen-induced tumorigenesis in a number of animal models (50) (51) (52) (53) (54) (55) (56) . Butylated hydroxyanisole (BHA) stimulates UDP-glucuronyltransferase activity, and this appears to be the mechanism by which BHA inhibits benzo[a]pyrene tumorigenesis in the mouse forestomach (57, 58) .
Scavengers ofElectrophiles and Free Radicas. Scavenging or trapping agents are compounds that physically react with the activated (electrophilic) forms of carcinogens and oxygen free radicals. Ellagic acid reacts directly with the diolepoxide of benzo[a]pyrene (BPDE) to form both cisand trans-adducts (59); such activity may account for its inhibition of BPDE-induced mutagenicity and carcinogenicity (60, 61) .
The sulfhydryl moiety of N-acetylcysteine (NAC) can accept electrophilic species, which may account for its antimutagenic and anticarcinogenic effects (62) (63) (64) .
Oxygen free radicals are produced by the metabolism of several carcinogens and by inflammatory cells (65) . Numerous chemopreventive agents exhibit antioxidant activity through their ability to scavenge oxygen radicals, including, for example, singlet oxygen, peroxy radicals, superoxide anion, and hydroxyl radicals. For example, NAC and other chemopreventive thiols are known to react with hydroxyl radicals (66) . The reaction of ,B-carotene with singlet oxygen and its participation in other free radical-trapping reactions is well documented (67, 68) . Phenolic antioxidants are known to scavenge peroxy radicals; in particular, vitamin E is known to scavenge peroxy radicals, singlet oxygen, and superoxide radicals (69) . Other phenols such as ellagic acid, curcumin, caffeic acid phenyl ester, and the tea polyphenols are particularly active oxygen radical scavengers, due likely to the presence of hydroxyl groups on adjacent carbons in these compounds. Nonphenolic antioxidants also scavenge oxygen free radicals. For example, glutathione reacts with alkyl-peroxy radicals (69) . A disadvantage of scavenging agents is that they must be present at sufficient concentrations in target tissues at all times during which carcinogens or free radicals are present.
Inducers ofDNA Repair. There are three possible chemopreventive mechanisms that involve DNA repair (70, 71) . The first is an increase in the overall level of DNA repair. An example of a naturally occurring chemical that increases the level of DNA repair is vanillin, which inhibits mammalian cell mutagenicity (72) . The mechanisms through which vanillin promotes DNA repair have not been determined. Second, the enzyme poly(ADP-ribosyl)transferase (ADPRT) is involved in modulation of DNA damage (73, 74) , and the level of this enzyme is reduced by chemical carcinogens (75) . N-Acetylcysteine prevents the decrease in ADPRT caused by the carcinogen 2-acetylaminofluorene (AAF) (75) . The third mechanism is suppression of errorprone DNA repair. Protease inhibitors depress error-prone repair in bacteria (76) , and it has been suggested that they could prevent carcinogenesis by inhibiting an error-prone repair system activated by proteases that, in turn, are induced by tumor promoters (77 (Table 3) . Inhibiters ofPolyamine Metabolism. The polyamine content of cells is correlated to their proliferative, and often their neoplastic, capabilities (81) . A key enzyme in the polyamine biosynthetic pathway, ornithine decarboxylase (ODC), catalyzes the conversion of ornithine to putrescine (82) . The levels of ODC and polyamines are frequently elevated in tumor tissues relative to their normal counterparts. In addition, phorbol ester tumor promoters such as 12-tetradecanoylphorbol-13-acetate (TPA) cause increased ODC activity and accumulation of polyamines in affected tissues (83) . Inhibitors of polyamine metabolism include the suicide inhibitor of ODC, a-difluoromethylornithine (DFMO) (84) . DFMO inhibits tumorigenesis induced by a number of different carcinogens (85) (86) (87) (88) (89) (90) (91) (92) .
Other chemopreventive agents such as the tea polyphenols, ellagic acid, and curcumin, inhibit ODC activity; presumably, this is one mechanism through which these compounds inhibit TPA-induced tumor promotion in mouse skin. Due to the rapid turnover of ODC (81) , constant levels of a given ODC inhibitor must be maintained at the target organ to achieve the desired antiproliferative activity.
Inducers (94) . Studies in hamster trachea (95) (96) (97) show that treatment of squamous keratinizing epithelium with vitamin A restores normal mucociliary differentiation. Retinoids appear to control differentiation via intracellular binding proteins and nuclear receptors (98) (99) (100) .
Calcium and vitamin D3 are differentiating agents that also inhibit carcinogenesis in animal models. Calcium induces differentiation in a number of epithelial tissues, including mouse skin (101), rat esophagus (102) , human colon (103), and human mammary gland (104, 105 (70, 71) .
Further, invocation of the signal transduction pathways provides a mechanistic rationale for the multiple chemopreventive effects of some agents. For example, agents such as the retinoids and PKC inhibitors, which affect activities at the cell membrane, cytoplasmic, and nuclear membrane levels, can also affect other connected events such as growth factor expression and polyamine metabolism (70, 71 (117, 118) showed that D-limonene, found in citrus oils, inhibits the progression of mammary tumors induced in rats by either MNU or DMBA. They also showed that D-limonene inhibits farnesylation of small G proteins; these data suggest that D-limonene prevents oncogene activation by inhibiting posttranslational farnesylation of the ras p21 protein (119) .
Investigations in vitro indicate inhibition of oncogene expression as a mechanism for inhibitory activity of protease inhibitors and retinoids. For example, the protease inhibitors 6-aminocaproic acid, leupeptin, and antipain inhibit transformation of NIH-3T3 cells transfected with activated H-ras oncogenes (120). Retinoic acid also inhibits H-ras-induced transformation in NIH-3T3 cells (120 (126) . This enhancement of communication correlated with inhibition of transformation of these cells and was mediated by upregulation of connexin proteins involved in gap-junction formation (126) .
Restorers of Immune Response. Chemopreventive agents influence the immune response through a number of mechanisms. For example, retinoic acid increases cell mediated and natural killer (NK) cell cytotoxicity; retinoids also cause leukemic promyelocytes to differentiate to mature granulocytes comparable to mature neutrophils (127) . These effects might be partially responsible for the activity of retinoids against established tumors (128) . Both thymocytes and NK cells from selenium-deficient mice have a decreased ability to destroy tumor cells in vitro (129) . Supplementation with 0.5 or 2 ppm selenium enhances the ability of rat NK cells to kill tumor cells.
Vitamin E also produces stimulatory effects on the immune system. Pharmacological doses of vitamin E fed with normal animal diets increases humoral antibody production, especially IgG (130) . Vitamin E also stimulates cell mediated immunity (131) and prevents the carcinogen-induced decrease in the density of macrophage-equivalent cells (Langerhans cells) in the oral cavity of DMBA-treated hamsters (132) .
Inducers ofApoptosis. Apoptosis (programmed cell death) is a well-regulated function of the normal cell cycle (133, 134) . Tumor suppressors, such as wild-type p53 (135, 136) , and growth factors, such as TGF-f (137), have been implicated as inducers of apoptosis. Apoptosis is inhibited by tumor promoters such as TPA (136, 137) and other chemicals that stimulate cell proliferation, such as hormones (134, 138, 139 (134) . Apoptosis in colonic tissues is induced by sulindac sulfone, a metabolite of the nonsteroidal anti-inflammatory drug (NSAID) sulindac (140) . This may be a major mechanism by which sulindac inhibits development of polyps in the human colon (141, 142) .
Correctors of DNA Methylation Imbalances. A number of studies have shown that methyl-deficient diets increase cell turnover and promote the development of carcinogen-induced liver tumors in rats and mice (143) (144) (145) (146) . In contrast, methyl-rich (fortified with choline and methionine) diets prevent or reduce these effects in the liver (147) (148) (149) . Changes in the expression levels of protooncogenes and decreased expression of growth factors and growth factor receptors occur in animals on methyl-deficient diets (143, 150, 151) . The increased protooncogene expression correlates with hypomethylation of the protooncogenes (143, 150) . Collectively, these data suggest that hypomethylation of DNA results in changes in the expression of genes involved in cellular growth control (143, 148) . Certain compounds that serve as methyl group donors inhibit tumorigenesis. Methionine, which is involved with choline, folic acid, and vitamin B12 in regulating intracellular methyl metabolism, inhibits chemically induced mammary cancer in rats; choline inhibits chemically induced liver tumors in rats (143, 145) .
Inhibitors ofBasement Membrane Degradation. Cancer cells produce various enzymes that digest the basement membrane and allow the cells to invade through normal tissues. These enzymes include the proteases collagenase, hyaluronidase, cathepsin B, elastase, and plasminogen activators (120, 152) . Protease inhibitors inhibit the activities of type IV collagenase and thrombin, which are among the proteases that participate in the destruction of the basement membrane during tumor invasion (120) . Thus protease inhibitors may exert their protective effects in part by inhibiting the degradation of the basement membrane.
Inhibitors of Arachidonic Acid Metabolism. Among the multiple events that occur during experimentally induced tumor promotion is an increased metabolism of arachidonic acid, which contributes to an overall inflammatory response (81) . The cyclooxygenase pathway converts arachidonic acid to prostaglandins, prostacyclins, and thromboxanes, while lipoxygenase conveirts arachidonic acid to leukotrienes and hydroxyeicosatetraenoic acids (153) . Activated oxygen species and alkylperoxy species are formed throughout this process. Relative to these events, the cyclooxygenase inhibitors such as NSAIDs (e.g., aspirin, indomethacin, ibuprofen, piroxicam) and certain antioxidants (e.g., flavonoids) are effective inhibitors of carcinogenesis (153) (154) (155) (156) (157) . Compounds that inhibit lipoxygenase, such as vitamin E, inhibit tumor promotion in mouse skin. Likewise, lipoxygenase inhibitors that are stable oneelectron donors-which competitively inhibit the production of unstable free radicals and electrophiles by prostaglandin H synthase (e.g., curcumin, the tea polyphenols, the flavonoids)-also inhibit tumor promotion in mouse skin (158) (159) (160) . Since the products of arachidonic acid metabolism could contribute to both the initiation and promotion/progression stages of carcinogenesis, inhibitors of arachidonic acid metabolism may act as either blocking agents or suppressing agents.
Kelloff et al. (70, 71) have discussed other mechanisms by which suppressing agents might inhibit molecular and cellular events associated with the promotion/progression stages of carcinogenesis; e.g., restoration of tumor suppressor function, inhibition of angiogenesis, and activation of antimetastasis genes. Although these are logical targets for chemoprevention, at present there is little evidence to suggest that known chemopreventive agents act through these mechanisms.
Future Prospects and Obstacles to Overcome
The large body of information on carcinogenesis and chemopreventive mechanisms that has been summarized in this report has been developed, for the most part, in the past 15 to 20 years. This information provides a strong base for future mechanistic studies in chemoprevention as well as for the design and development of clinical investigations. Indeed, a number of phase I, II, and III clinical trials of chemopreventive agents are underway and some success has already been achieved. For example, Hong et al. (161) showed that isotretinoin inhibited the development of second primary tumors in patients treated for primary cancers of the head and neck. Garewal et al. (162) showed regression of oral leukoplakia in individuals treated with P-carotene. Several studies have demonstrated the ability of the nonsteroidal antiinflammatory agent, sulindac, to cause regression of colonic polyps (141, 142) .
However, the results of some clinical trials have not been as promising, and future success in clinical trials is needed to further establish chemoprevention as a plausible approach to the prevention of human cancer. In this respect, the progressive increase in research activity on the basic mechanisms of action of chemopreventive agents during the past few years is gratifying and is likely to result in an even stronger database from which to design clinical trials in the future.
In a previous report (1), we discussed in considerable detail some of the obstacles to be overcome in the field of cancer chemoprevention. Among these is the relative lack of participation of the pharmaceutical industry. A major concern of the pharmaceutical industry is the length of time and the cost to conduct phase III 
